Dermatology Times, March 2020 (Vol. 41, No. 3)

Interleukin-29 for inflammatory autoimmune diseases

October 29, 2019

Interleukin-29 (IL-29) is a newly discovered cytokine that has become the subject of increased research attention for its role in inflammation and inflammatory autoimmune disorders and therefore as a target for novel therapeutic development.

Topical probiotics may restore skin microflora, decrease acne lesions

December 19, 2019

Topical probiotics could promote a positive bacterial balance in the skin – similar to how oral probiotics increase diversity of flora in the gut – and may improve skin conditions, such as acne, say authors of a recent review.

Standard of care for primary cutaneous melanoma evolves

March 09, 2020

Though still considered controversial, several evolving treatment and management plans for primary cutaneous melanoma are making their way into the mainstream and challenging more traditional approaches.

Atopic dermatitis pipeline full of potential

March 09, 2020

Atopic dermatitis therapy is currently undergoing a revolution that promises to treat patients of all ages who are suffering from every aspect of the disease-from rashes, itch and sleep disturbances, to secondary effects, like anxiety and depression.

Topical rosacea cream creates new treatment paradigm

March 11, 2020

Topical ivermectin cream, 1% (Soolantra, Galderma) represents an advance in treatment for rosacea, offering superior efficacy and tolerability compared with previously available therapies, says Jeffrey S. Fromowitz, M.D., who spoke at the Orlando Dermatology Aesthetic & Clinical Conference.

Anti-TNF therapy efficacy differs by gender

March 16, 2020

A study showing differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders may be helpful to dermatologists as they consider treatment for patients with moderate-to-severe psoriasis, according to the investigators.

Atopic dermatitis patients need better disease control

March 17, 2020

Adult patients with moderate-to-severe atopic dermatitis who were treated with systemic agents, including cyclosporine, azathioprine, mycophenolate mofetil, methotrexate or cyclophosphamide, reported a high level of disease-related burden despite those treatments, says a recent study.

Adjunct therapies may support fractional CO2

March 23, 2020

Although the fractional ablative CO2 laser is a first-line treatment for acne scarring, the potential for side effects from repetitive treatments leaves room for improvement with additive therapies, according to a recent review.

Rhinophyma treatment, prevention strategies

March 23, 2020

Rhinophyma is a disfiguring condition with deleterious psychosocial and functional consequences, and its pathogenesis remains unclear. Deborah S. Sarnoff, M.D., offers insight on its etiology, and treatment options in this article.